182 related articles for article (PubMed ID: 27914946)
1. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors.
Garg G; Zhao H; Blagg BS
Bioorg Med Chem; 2017 Jan; 25(2):451-457. PubMed ID: 27914946
[TBL] [Abstract][Full Text] [Related]
2. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors.
Byrd KM; Subramanian C; Sanchez J; Motiwala HF; Liu W; Cohen MS; Holzbeierlein J; Blagg BS
Chemistry; 2016 May; 22(20):6921-31. PubMed ID: 27037933
[TBL] [Abstract][Full Text] [Related]
4. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer.
Forsberg LK; Liu W; Holzbeierlein J; Blagg BSJ
Bioorg Med Chem Lett; 2017 Sep; 27(18):4514-4519. PubMed ID: 28844386
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
[TBL] [Abstract][Full Text] [Related]
6. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.
Peterson LB; Blagg BS
Bioorg Med Chem Lett; 2010 Jul; 20(13):3957-60. PubMed ID: 20570149
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors.
Byrd KM; Kent CN; Blagg BSJ
ChemMedChem; 2017 Dec; 12(24):2022-2029. PubMed ID: 29058824
[TBL] [Abstract][Full Text] [Related]
9. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
[TBL] [Abstract][Full Text] [Related]
10. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.
Zhao H; Anyika M; Girgis A; Blagg BS
Bioorg Med Chem Lett; 2014 Aug; 24(15):3633-7. PubMed ID: 24953820
[TBL] [Abstract][Full Text] [Related]
11. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.
Zhao H; Donnelly AC; Kusuma BR; Brandt GE; Brown D; Rajewski RA; Vielhauer G; Holzbeierlein J; Cohen MS; Blagg BS
J Med Chem; 2011 Jun; 54(11):3839-53. PubMed ID: 21553822
[TBL] [Abstract][Full Text] [Related]
12. Novobiocin Analogues That Inhibit the MAPK Pathway.
Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
[TBL] [Abstract][Full Text] [Related]
13. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity.
Zhang Z; Banerjee M; Davis RE; Blagg BSJ
Bioorg Med Chem Lett; 2019 Nov; 29(22):126676. PubMed ID: 31591016
[TBL] [Abstract][Full Text] [Related]
15. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
Kusuma BR; Duerfeldt AS; Blagg BS
Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
[TBL] [Abstract][Full Text] [Related]
17. Novobiocin-ferrocene conjugates possessing anticancer and antiplasmodial activity independent of HSP90 inhibition.
Mbaba M; de la Mare JA; Sterrenberg JN; Kajewole D; Maharaj S; Edkins AL; Isaacs M; Hoppe HC; Khanye SD
J Biol Inorg Chem; 2019 Mar; 24(2):139-149. PubMed ID: 30542925
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors.
Duerfeldt AS; Brandt GE; Blagg BS
Org Lett; 2009 Jun; 11(11):2353-6. PubMed ID: 19435295
[TBL] [Abstract][Full Text] [Related]
20. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
